申请人:SMITH KLINE & FRENCH LABORATORIES
LIMITED
公开号:EP0197664A2
公开(公告)日:1986-10-15
Compounds of the formula (I) : and pharmaceutically acceptable salts are described, wherein R' is hydrogen or methyl; and R2 and R3 are independently hydrogen, C1-4alkyl, phenyl(C1-4)alkyl or pyridyl(C1-4)alkyl, any of such groups being optionally substituted by one or two hydroxy, C1- 4alkoxy or C1-4 alkyl groups; or R2 and R3 together with the carbon atoms to which they are joined form a benzene ring which is optionally substituted by C1- 4alkyl.
These compounds have inotropic, vasodilator, bronchodilating and platelet aggregation inhibiting properties. Pharmaceutical compositions are described as are methods of use. Intermediates and processes for the preparation of the compounds of the formula (I) are described.
所述的式(I):化合物及药学上可接受的盐类,其中 R' 为氢或甲基;R2 和 R3 独立地为氢、C1-4烷基、苯基(C1-4)烷基或吡啶基(C1-4)烷基,其中任一基团可任选被一个或两个羟基、C1-4烷氧基或 C1-4 烷基取代;或 R2 和 R3 与它们连接的碳原子一起形成一个苯环,该苯环可任选被 C1-4 烷基取代。
这些化合物具有肌力、血管扩张、支气管扩张和血小板聚集抑制特性。此外,还介绍了药物组合物以及使用方法。还描述了制备式 (I) 化合物的中间体和工艺。